Trials / Recruiting

RecruitingNCT06636734

Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

A Phase II Trial Of Lovastatin And Pembrolizumab In Patients With RM HNSCC (LAPP)

Status: Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 28 (estimated)

Sponsor: Emory University · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This phase II trial tests how well lovastatin and pembrolizumab work in treating patients with head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Lovastatin is a drug used to lower the amount of cholesterol in the blood and may also cause tumor cell death. In addition, studies have shown that lovastatin may make the tumor cells more sensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lovastatin and pembrolizumab may kill more tumor cells in patients with recurrent or metastatic head and neck cancer.

Detailed description

PRIMARY OBJECTIVE: I. To evaluate anti-tumor activity of the combination of pembrolizumab and lovastatin by assessing the objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST 1.1). SECONDARY OBJECTIVE: I. To evaluate the anti-tumor activity of the combination of by assessing progression-free survival (PFS) and overall survival (OS). TERTIARY/EXPLORATORY OBJECTIVES: I. To assess the effects of the combination of lovastatin + pembrolizumab on immune cells in blood. II. To assess the association between efficacy measures and expression in tumors. III. To assess the association between anti-tumor activity and immune cells in the blood. OUTLINE: Patients receive lovastatin orally (PO) once daily (QD) and pembrolizumab intravenously (IV) over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection, and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT throughout the study. After completion of study treatment, patients are followed for up to 2 years.

Conditions

Interventions

Type	Name	Description
PROCEDURE	Biospecimen Collection	Undergo blood sample collection
PROCEDURE	Computed Tomography	Undergo CT or PET/CT
DRUG	Lovastatin	Given PO
PROCEDURE	Magnetic Resonance Imaging	Undergo MRI
BIOLOGICAL	Pembrolizumab	Given IV
PROCEDURE	Positron Emission Tomography	Undergo PET/CT

Timeline

Start date: 2024-12-09
Primary completion: 2027-12-31
Completion: 2028-12-31
First posted: 2024-10-15
Last updated: 2026-02-11

Locations

2 sites across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06636734. Inclusion in this directory is not an endorsement.